Skip to main content

Dementia With Lewy Bodies Risk Down With α-1 Adrenergic Receptor Antagonists

Medically reviewed by Carmen Pope, BPharm. Last updated on June 20, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, June 19, 2024 -- Men taking α-1 adrenergic receptor antagonists terazosin, doxazosin, and alfuzosin (Tz/Dz/Az) seem to have a lower risk for dementia with Lewy bodies (DLB), according to a study published online June 19 in Neurology.

Alexander Hart, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues used a new-user active comparator design in the Merative Marketscan database to identify men with no history of DLB who were newly initiated on Tz/Dz/Az or two comparator medications (α-1 adrenergic receptor antagonist tamsulosin or 5α-reductase inhibitor [5ARI]) to examine the potential neuroprotective effects of Tz/Dz/Az.

The researchers found that the risk for developing DLB was lower for men who were newly started on Tz/Dz/Az than those taking tamsulosin or 5ARI (hazard ratios, 0.60 and 0.73, respectively), while the risk was similar for men taking tamsulosin versus 5ARI. The results were robust to sensitivity analyses.

"More research is needed to follow people over time and determine whether there is a cause-and-effect relationship here, but it is promising to think that these drugs could have a protective effect on this disease that will likely affect a larger number of people as the population ages," coauthor Jacob E. Simmering, Ph.D., of the University of Iowa in Iowa City, said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Doctors' Preferences for Their Own End-of-Life Care? No Life-Sustaining Practices

FRIDAY, June 13, 2025 -- Many physicians would personally prefer to avoid life-sustaining practices if they had advanced cancer or Alzheimer disease, according to a study...

Shorter Leukocyte Telomere Length Linked to Higher Incidence of Age-Related Brain Diseases

THURSDAY, June 12, 2025 -- Individuals with shorter leukocyte telomere length (LTL) have a higher incidence of stroke, dementia, and late-life depression (LLD), individually and...

Epilepsy More Common With Frontotemporal Dementia

TUESDAY, June 10, 2025 -- Epilepsy is more common among those with frontotemporal dementia (FTD) than among people with Alzheimer disease (AD) or healthy controls, according to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.